For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantbio, Inc.

USPTO Granted Patents = 58

EPO Patents = 7

Forward Citations = 43

Loading Chart...

Loading Chart...

63 inventors (with patents filed for the assignee):

Kayvan R Niazi (42 out of 101 patents)

Patrick Soon-Shiong (17 out of 476 patents)

Clifford Anders Olson (15 out of 17 patents)

4. Shahrooz Rabizadeh (11 out of 86 patents)

5. Shiho Tanaka (9 out of 13 patents)

6. Chunlin Tao (8 out of 32 patents)

7. Philip T Liu (7 out of 10 patents)

8. Qinwei Wang (7 out of 14 patents)

9. Wael Tadros (7 out of 7 patents)

10. Nicholas James Witchey (7 out of 160 patents)

11. Stephen Charles Benz (6 out of 57 patents)

12. Peter Sieling (6 out of 8 patents)

13. Raymond Wong (6 out of 9 patents)

14. Paul Weingarten (6 out of 10 patents)

15. Heather McFarlane (5 out of 5 patents)

Core Competencies:

Multi-Pulse Transfection

Chimeric Antigen Receptors

Monoclonal Antibodies

Cellular Adjuvants

T Cell Expansion

Neoepitope Payload

Mesenchymal Stem Cells

Live Cell Imaging

Tumor Characterization

Recombinant NK Cells

mRNA Display Library

Viral Infection

58 patents: Sort by Forward Citations

1. 12758588 - Mesenchymal stem cell derived exosomes and methods (2026-10-13),

2. 12662681 - Multi-pulse transfection methods and cells (2026-06-23),

3. 12638456 - Cellular reporting for therapy production (2026-05-26),

4. 12595307 - Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors (2026-04-07),

5. 12545928 - Machine Methods To Determine Neoepitope Payload Toxicity (2026-02-10),

6. 12502404 - Conditional modulation of therapy using recombinant cells (2025-12-23),

7. 12416635 - Live cell imaging systems and methods to validate triggering of immune response (2025-09-16),

8. 12412639 - Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples (2025-09-09),

9. 12397019 - Mesenchymal stem cell derived exosomes and methods (2025-08-26),

10. 12385903 - RP182 compositions and methods (2025-08-12),

11. 12350323 - Cellular adjuvants for viral infection (2025-07-08),

12. 12350316 - IL7-IL 15 TxM compositions and methods (2025-07-08),

13. 12329809 - Cellular adjuvants for viral infection (2025-06-17),

14. 12308095 - Prediction of computational pathway circuits (2025-05-20),

15. 12280092 - Reprogrammed T cell-like NK cells (2025-04-21),

Company Overview

Nantbio, Inc., based in Culver City, CA, specializes in the development of innovative immunotherapy solutions aimed at enhancing cancer treatment. The company focuses on advanced technologies such as multi-pulse transfection and chimeric antigen receptors, which are pivotal in creating targeted therapies. Additionally, Nantbio is engaged in the research of monoclonal antibodies, cellular adjuvants, and T cell expansion techniques, leveraging neoepitope payloads and mesenchymal stem cells to improve therapeutic efficacy. Their commitment to live cell imaging further supports the advancement of personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

58 Patents

#8 in Culver City, CA

#1,445 in California

#6,157 in US

#12,395 in the World

Culver City, CA, United States of America

Nantbio, Inc.

Forward Citations = 43

63 inventors:

Kayvan R Niazi (42 out of 101 patents)

Patrick Soon-Shiong (17 out of 476 patents)

Clifford Anders Olson (15 out of 17 patents)

4. Shahrooz Rabizadeh (11 out of 86 patents)

5. Shiho Tanaka (9 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nantbio, Inc.. Retrieved from https://idiyas.com/company/nantbio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…